Lymphokine-activated cytotoxicity in peripheral blood mononuclear cells of severely immunocompromised HIV-infected patients

Scandinavian Journal of Immunology

Volumn 45, Issue 1, 1997, Pages 91-95

  Forthal, D N ^a,b   Landucci, G ^a   Robinson Jr , W E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; RECOMBINANT GAMMA INTERFERON;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOKINE ACTIVATED KILLER CELL; NATURAL KILLER CELL; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; SERUM;

EID: 0031021386     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1997.d01-367.x     Document Type: Article

References (25)

1. Tartter PI, Steinberg B, Barron DM, Martinelli G. The prognostic significance of natural killer cytotoxicity in patients with colorectal cancer. Arch Surg 1987;122:1264-8.
2. Whiteside TL, Herberman RB. The role of natural killer cells in human disease. Clin Immunol Immunopath 1989;53:1-23.
3. Murayama T, Cai Q, Rinaldo C. Antibody-dependent cellular cytotoxicity mediated by CD16+ lymphocytes from HIV-seropositive homosexual men. Clin Immunol Immunopath 1990;55:297-304.
4. Brenner BG, Gryllis C, Gornitsky M, Cupples W, Wainberg M. Differential effects of chemotherapy-induced and HIV-1-induced immunocompromise on NK and LAK activities using breast cancer and HIV-1 seropositive patient populations. Anticancer Research 1991;11:969-74.
5. Gryllis C, Wainberg M, Bentwich Z, Gornitsky M, Brenner BG. Increased LAK activity against HIV-infected cell lines in HIV-1 + individuals. Clin Exp Immunol 1992;89:356-61.
6. Gomez MJ, Torosantucci A, Quinti I, Testa U, Peschle C. Cassone A. Mannoprotein-induced anti-U937 cell cytotoxicity in peripheral blood mononuclear cells from uninfected or HIV-infected subjects: role of interferon-gamma and tumor necrosis factor-α. Cell Immunol 1993;530-43.
7. Algara-Scott D, Vuillier F, Cayota A, Dighiero G. Natural killer (NK) cell activity during HIV infection: a decrease in NK activity is observed at the clonal level and is not restored after in vitro long-term culture of NK cells. Clin Exp Immunol 1992;90:181-7.
8. Gryllis C, Wainberg MA, Gornitsky M, Brenner B. Diminution of inducible lymphokine-activated killer cell activity in individuals with AIDS-related disorders. AIDS 1990;4:1205-12.
9. Cauda R, Tumbarello M, Ortona L et al. Inhibition of lymphokine-activated killer activity during HIV infection: role of HIV-1 gp41 synthetic peptides. Nat Immun Cell Growth Regul 1990;9:366-75.
10. Rook AH, Masur H, Lane HC et al. Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. J Clin Invest 1983;72:398-403.
11. Lifson JD, Benike CJ, Mark DF, Koths K, Engleman EG. Human recombinant interleukin-2 partly reconstitutes deficient in-vitro immune responses of lymphocytes from patients with AIDS. Lancet 1984;1:698-702.
12. Pross HF, Baines MG, Rubin P, Shragge P, Patterson MS. Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity. J Clin Immunol 1981;1:51-63.
13. Zielske JV, Golub SH. Fetal calf serum-induced blastogenic and cytotoxic responses of human lymphocytes. Cancer Research 1976;36:3842-6.
14. Rook AH, Hooks JJ, Quinnan GV et al. Interleukin 2 enhances the natural killer cell activity of acquired immunodeficiency syndrome patients through a gamma-interferon-independent mechanism. J Immunol 1985;134:1503-7.
15. Bonavida B, Katz J, Gottlieb M. Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. J Immunol 1986;137:1157-63.
16. Alcocer-Varela J, Alarcon-Segovia D, Abud-Mendoza C. Immunoregulatory circuits in the acquired immune defiency syndrome and related complex. Production of and response to interleukins 1 and 2, NK function and its enhancement by interleukin-2 and kinetics of the autologous mixed lymphocyte reaction. Clin Exp Immunol 1985;60:31-8.
17. Rappocciolo G, Toso JF, Torpey DJ III, Gupta P, Rinaldo CR Jr. Association of alpha interferon production with natural killer cell lysis of U937 cells infected with human immunodeficiency virus. J Clin Microbiol 1989;27:41-8.
18. Masur H, Ognibene FP, Yarchoan R et al. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann Inter Med 1989;111:223-31.
19. Kovacs JA, Baseler M, Dewar RJ et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. New Eng J Med 1995;332:567-75.
20. Clerici M, Lucey DR, Berzofsky JA et al. Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. Science 1993;262:1721-4.
21. Lacey DR, Melcher GP, Hendrix CW. Human immunodeficiency virus infection in the US Air Force: seroconversions, clinical staging, and assessment of a T helper cell functional assay to predict change in CD4+ T cell counts. J Infect Dis 1991;164:631-7.
22. Vigano A, Principi N, Villa ML et al. Immunologic characterization of children vertically infected with human immunodeficiency virus, with slow or rapid disease progression. J Pediat 1995;126:368-74.
23. Creemers PC, Stark DF, Boyko WJ. Evaluation of natural killer cell activity in patients with persistant generalized lymphadenopathy and acquired immunodeficiency syndrome. Clin Immunol Immunopathol 1985;36:141-50.
24. Cauda R, Tumbarello M, Ortona L et al. Inhibition of normal human natural killer cell activity by human immunodeficiency virus synthetic transmembrane peptides. Cell Immunol 1988;115:57-65.
25. Pedersen BK, Thomsen BS, Nielsen H. Inhibition of natural killer cell activity by antigen-antibody complexes. Allergy 1986;41:568-74.